CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

Patients with diffuse midline glioma (DMG) harboring H3 K27M mutation rarely survive longer than two years and have no proven therapies following first-line radiation. ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has shown encouraging efficacy in early phase studies in H3 K27M-muta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Rahman Kawakibi, Abed, Tarapore, Rohinton S, Gardner, Sharon, Thomas, Chase, Cartaxo, Rodrigo, Yadav, Viveka Nand, Chi, Andrew, Kurz, Sylvia, Wen, Patrick, Arrillaga-Romany, Isabel, Batchelor, Tracy, Butowski, Nicholas, Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca, de Groot, John, Mehta, Minesh, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Cloughesy, Timothy, Ellingson, Benjamin, Umemura, Yoshie, Garton, Hugh, Franson, Andrea, Robertson, Patricia, Schwartz, Jonathan, Cantor, Evan, Miklja, Zachary, Mullan, Brendan, Bruzek, Amy, Siada, Ruby, Cummings, Jessica, Paul, Alyssa, Wolfe, Ian, Jiang, Li, Filbin, Mariella, Vats, Pankaj, Kumar-Sinha, Chandan, Mody, Rajen, Chinnaiyan, Arul, Venneti, Sriram, Lu, Guangrong, Mueller, Sabine, Martinez, Daniel, Resnick, Adam, Nazarian, Javad, Waszak, Sebastian, Allen, Joshua, Koschmann, Carl
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650384/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.184
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars